For the quarter ending 2026-03-31.
| Income Statement | 2026-03-31 | 2025-12-31 | 2025-09-30 | 2025-06-30 |
|---|---|---|---|---|
| Research and development | 1,607 | 2,050* | 2,964 | 1,750 |
| General and administrative | 6,830 | 6,010* | 4,378 | 5,213 |
| Total operating expenses | 8,437 | 8,060 | 7,342 | 6,963 |
| Loss from operations | -8,437 | -8,060* | -7,342 | -6,963 |
| Interest income | 394 | 362* | 279 | 155 |
| Interest expense | - | 29* | 15 | 13 |
| Change in fair value of warrant liability | 4,780 | 141* | -1,067 | -374 |
| Total other income (expenses) | -4,386 | 192* | 1,331 | 516 |
| Net income (loss) | -12,823 | -7,869* | -6,011 | -6,447 |
| Dividend to series b-1 preferred stockholders | - | - | - | 0 |
| Net income attributable to participating securities | - | - | - | 0 |
| Unrealized loss on marketable securities, net | -1 | 0* | - | - |
| Net loss attributable to common stockholders | - | - | -6,011 | -6,447 |
| Net comprehensive income (loss) | -12,824 | -7,869 | - | - |
| Basic EPS | -0.54 | -0.455 | -0.33 | -0.52 |
| Diluted EPS | -0.54 | -0.455 | -0.33 | -0.52 |
| Basic Average Shares | 23,908,153 | 17,293,180 | 18,065,389 | 12,302,059 |
| Diluted Average Shares | 23,908,153 | 17,293,180 | 18,065,389 | 12,302,059 |
Unicycive Therapeutics, Inc. (UNCY)
Unicycive Therapeutics, Inc. (UNCY)